Alzamend Neuro (ALZN) Non Operating Income (2020 - 2026)
Alzamend Neuro's (ALZN) quarterly Non Operating Income came in at $928.0 in Q2 2026, up 282.32% year-over-year from $242.73 in Q2 2025, and up 169.41% quarter-over-quarter from -$1337.0 in Q1 2026.
Powered by 
Analysis
Alzamend Neuro (ALZN) Non Operating Income (2020 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Non Operating Income across 7 years of filings, most recently posting $928.0 for Q2 2026.
- In Q2 2026, Non Operating Income rose 282.32% year-over-year to $928.0; the TTM figure through Apr 2026 stood at -$5541.0 (up 69.27% YoY), while the FY2026 annual figure was -$5541.0, up 69.27% from the prior year.
- Non Operating Income came in at $928.0 for Q2 2026 at Alzamend Neuro, up from -$1337.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3398.0 in Q2 2022 to a low of -$16299.0 in Q1 2022.
- Average Non Operating Income over 5 years is -$3015.1, with a median of -$2040.5 recorded in 2023.
- Year-over-year, Non Operating Income tumbled 554.28% in 2024 and jumped 282.32% in 2026.
- Over 5 years, Non Operating Income stood at -$3588.0 in 2022, then slipped by 20.15% to -$4311.0 in 2023, then grew by 18.93% to -$3495.0 in 2024, then gained by 24.21% to -$2649.0 in 2025, then soared by 135.03% to $928.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $928.0 in Q2 2026, -$1337.0 in Q1 2026, and -$2649.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Alzamend Neuro | 5.54 Mn | 5.54 Mn | - | 928.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 928.00 |
| Jan 31, 2026 | -1,337.00 |
| Oct 31, 2025 | -2,649.00 |
| Jul 31, 2025 | -2,483.00 |
| Apr 30, 2025 | -509.00 |
| Jan 31, 2025 | -2,019.00 |
| Oct 31, 2024 | -3,495.00 |
| Jul 31, 2024 | -12,006.00 |
| Apr 30, 2024 | -1,465.00 |
| Jan 31, 2024 | -2,488.00 |
| Oct 31, 2023 | -4,311.00 |
| Jul 31, 2023 | -1,835.00 |
| Apr 30, 2023 | -519.00 |
| Jan 31, 2023 | -2,062.00 |
| Oct 31, 2022 | -3,588.00 |
| Jul 31, 2022 | -1,532.00 |
| Apr 30, 2022 | 3,398.00 |
| Jan 31, 2022 | -16,299.00 |
| Oct 31, 2021 | -15,995.00 |
| Jul 31, 2021 | -13,628.00 |